# **Supplementary Materials**

**A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping**

Chiara Fabbri<sup>1</sup>, Siegfried Kasper<sup>2</sup>, Alexander Kautzky<sup>2</sup>, Joseph Zohar<sup>3</sup>, Daniel Souery<sup>4</sup>, Stuart Montgomery<sup>5</sup>, Diego Albani<sup>6</sup>, Gianluigi Forloni<sup>6</sup>, Panagiotis Ferentinos<sup>7</sup>, Dan Rujescu<sup>8</sup>, Julien Mendlewicz<sup>9</sup>, Rudolf Uher <sup>10</sup>, Cathryn M. Lewis<sup>1</sup>, Alessandro Serretti <sup>11</sup>

1: Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom

2: Department of Psychiatry and Psychotherapy, Medical University Vienna, Austria

3: Department of Psychiatry, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Israel

4: Laboratoire de Psychologie Medicale, Universitè Libre de Bruxelles and Psy Pluriel, Centre Européen de Psychologie Medicale, Brussels

5: Imperial College School of Medicine, London, UK

6: Laboratory of Biology of Neurodegenerative Disorders, Neuroscience Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

7: Department of Psychiatry, Athens University Medical School, Athens, Greece

8: University Clinic for Psychiatry, Psychotherapy and Psychosomatic, Martin-Luther-University Halle-Wittenberg, Germany

9: Universite´ Libre de Bruxelles

10: Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada

11. Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy

## **Table of contents**



## **Supplementary Methods**

## **DNA extraction in GSRD**

Genomic DNA was extracted from whole blood with an automated nucleic acid extractor (Maxwell, Promega, US). Quantity and quality were checked by a nanoscale spectrophotometer and for samples having a 260/280 absorbance ratio below 1.2 the extraction process was repeated.

## **Whole exome sequencing, genotyping and quality control in GSRD**

The initial quality control was performed using the FASTQ pipeline (1). Trimming of the reads with barcode sequences was performed with fastx trimmer from the fastx toolkit (2). To align the trimmed reads to the reference human genome (human assembly GRCh37/hg19) we used TopHat2 (3) with the parameters mate-inner-dist=118 for the paired reads, and mate-std-dev=52.

Variants were called using FreeBayes, a Bayesian genetic variant detector designed to find SNPs (single-nucleotide polymorphisms), indels (insertions and deletions), MNPs (multi-nucleotide polymorphisms), and complex events (composite insertion and substitution events). FreeBayes is haplotype-based, in the sense that it calls variants based on the literal sequences of reads aligned to a particular target, not their precise alignment. This method avoids one of the core problems with alignment-based variant detection that identical sequences may have multiple possible alignments (4). Poorly called variants were pruned out (quality score < 30, leaving in only variants with base call accuracy of 99.9% (5)) and variants with read depth  $\leq 10$  (6) were excluded. Variants with  $\geq 2\%$ missing rate, indels > 5 bp and SNPs within 3 bp from an indel (7), variants without at least two reads balanced to each side of the site (RPR  $\leq 1$  or RPL  $\leq 1$ ) or without reads on both strands (SAF=0 or SAR=0) (8) were also excluded. We excluded subjects having genotyping rate  $\leq$  95%, gender discrepancies, cryptic relatedness (identity by descent (IBD)>0.1875(9)), abnormal heterozygosity and population outliers (outside five standard deviations from the mean for the first 20 population principal components). After quality control, mean read depth was 79.82 (SD 62.15). Indels were realigned using left-normalization, and multiallelic variants were split into individual VCF lines using BCFtools (https://samtools.github.io/bcftools/bcftools.html).

Population principal components were calculated on a linkage-disequilibrium-pruned set of variants with MAF  $\geq$  0.02. Indeed it has been demonstrated that the inclusion of low frequency or rare variants does not improve the detection of population stratification (10).

Quality control of genome-wide data was performed in line with the criteria used for the exome sequence data and a previous study on this sample (11). Genome-wide data was imputed using the Michigan imputation server and the Haplotype Reference Consortium (HRC, version r1.1 2016) as reference panel (12). Only common variants (MAF > 0.02) were extracted from imputed data and pruned for poor imputation quality  $(R^2<0.30)$  (13).

The total number of rare and common variants shared between the exome sequence data and genomewide data was 161,130 and 129,610, respectively; 120,632 (74.9%) of the rare ones were imputed (in the array data) and 40,497 (25.1%) of them were sequenced/genotyped; 114,198 (88%) of the common variants were imputed (in the array data) and 15,412 were sequenced/genotyped. The shared variants were used to exclude samples with poor concordance as explained in the main manuscript (paragraph 3. Results).

### **Variant annotation and exome risk score in GSRD**

We classified variants into a high functional group and intermediate functional group according to functional consequence scores from the Sequence Ontology (SO) project (14). The first group included variants with a functional consequence score  $\geq 0.90$  (frameshift, stop gained, splice region, splice acceptor, splice donor, coding sequence, start lost, incomplete terminal codon, stop lost) and

the second group included variants with a functional consequence score  $\geq 0.70$  (protein altering, missense, initiator codon, inframe deletion, inframe insertion).

Exome risk scores were calculated using different weighting methods for comparison purpose (Eigen, CADD and SO functional scores) as described in paragraph 2.4.2. of the main manuscript. Eigen and CADD score were estimated using predictive modelling based on a wide range of variant annotations, describing variant risk of damaging effects based on conservation, impact on protein function, structure,

#### **Box 1**

- anyVariant 20
- maybeRegulatoryOrIntron 60
- alsoUTR 65
- coding 70
- nonsynonymous 90
- LOF 95
- polyphenProbablyOrPossiblyDamaging 95
- SIFTDeleterious 100

gene transcription, chromatin structure and others. Eigen scores differently from CADD scores were calculated using unsupervised machine learning, meaning that variants were not labelled as benign or damaging in the training set, but this distinction was figured out by the model based on a number of variant annotations (15). When using Eigen and CADD score, we extracted the raw scores and rescaled them between 1-25 (to not have negative values). The used weights based on SO functional scores are reported in Box 1. When we used SO functional scores, gene scores were calculated using GeneVarAssoc and getVarScores software (16). For scores based on common variants, we created clumps around variants prioritized according to their functional scores (the variant with the highest functional score was kept), using a  $R^2$  threshold of 0.5 and a window size of 30 Kbp. This approach was used instead of the classic clumping based on association p values because the scores we calculated were substantially based on variant functional consequences and not on the difference in frequency between cases and controls.

In terms of included gene sets, we downloaded Gene Ontology (GO), Reactome, Biocarta, KEGG and other canonical gene sets (pathway interaction database and signal transduction pathways) from the Molecular Signatures Database (MSigDB version 6.2) (17). In addition, we included gene sets from SynaptomeDB (18), gene sets previously associated with major depressive disorder (MDD) (19), schizophrenia (20) (21) or bipolar disorder (22). A total of 7266 gene sets and 18908 genes were considered. In order to avoid bigger genes from driving most of the effect of a gene set, we added a further weight ( $\omega_{size,m}$ ) that reduced the score of a gene as a function of its number of variants ( $\omega_{size,m}$  = 1+(*sm* − min{*si*})/(max{*si*}− min{*si*}), where *sm*: number of variants in a gene, min{si}: number of variants in the smallest gene, max $\{si\}$ : number of variants in the biggest gene) (23).

### **Replication samples: STAR\*D and GENDEP**

The Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) study was a NIMH-funded study aimed to determine the effectiveness of different treatments for patients with MDD who have not responded to the first antidepressant treatment. Non-psychotic MDD (DSM-IV criteria) patients with age between 18 and 75 years were enrolled from primary care or psychiatric outpatient clinics. Severity of depression was assessed using the 16-item Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C16) at baseline, weeks 2, 4, 6, 9, and 12, while HRSD–17 was administered at each level entry and exit. All patients received citalopram in level 1. Participants without sufficient symptomatic benefit were eligible for randomization to level 2 treatments, which entail four switch options (sertraline, bupropion, venlafaxine, cognitive therapy) and three citalopram augment options (bupropion, buspirone, cognitive therapy). 1953 patients were included in the genetic study. Detailed description of the study design and population are reported elsewhere (24).

The Genome-Based Therapeutic Drugs for Depression (GENDEP) project was a 12-week partially randomized open-label pharmacogenetic study with two active treatment arms. 867 patients with unipolar depression (ICD-10 or DSM-IV criteria) aged 19–72 years were recruited at nine European centres. Eligible participants were allocated to flexible-dosage treatment with either escitalopram (10–30 mg daily, 499 subjects) or nortriptyline (50–150 mg daily, 368 subjects). Severity of depression was assessed weekly by the Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Rating Scale for Depression (HRSD–17) and Beck Depression Inventory (BDI). Detailed information about the GENDEP study has been previously reported (25).

In STAR\*D longitudinal data referred to level 1 and level 2 were used to create the phenotypes. Response was defined as a QIDS-C16 < 13 [equivalent to MADRS of 22] and score decrease of at least 50% compared to baseline at level 1 exit, while TRD was defined as lack of response at level 2 exit. In GENDEP prospective data collected during the 12-week trial were combined with the retrospective information on previous antidepressant treatments of the current episode to determine the phenotypes. A decrease of at least 50% in MADRS score compared to baseline was used as the only criterion according to the available definition of response in this sample (26).

Genome-wide data in STAR\*D were obtained using Affymetrix Human Mapping 500K Array Set in 969 subjects and Affymetrix Genome-Wide Human SNP Array 5.0 (Affymetrix, South San Francisco, California) in the remaining 979 samples, while in GENDEP Illumina Human610-quad bead chip (Illumina, Inc., San Diego) was used (25) (27). Further genotyping in both samples was performed by the Illumina Infinium Exome-24 v1.0 BeadChip that includes  $\sim$  250K variants. Preimputation quality control was performed according to the following criteria: 1) variants with missing rate  $\geq$  5%; 2) monomorphic variants; 3) subjects with genotyping rate < 97%; 4) subjects with gender discrepancies; 5) subjects with abnormal heterozygosity; 6) related subjects (identity by descent  $(IBD) > 0.1875(9)$ ; 7) population outliers according to Eigensoft analysis of linkage-disequilibriumpruned genetic data (28); 8) GWAS-exome discordant and 9) non-white subjects in STAR\*D. The number of included subjects after quality control and their clinical-demographic features are reported in Supplementary Table 12.

Gene- and pathway-based scores were calculated in STAR\*D and GENDEP following the same approach used in GSRD. Rare and common variants were distinguished based on the MAF threshold  $1/\sqrt{2n}$ ) where n was the sample size (29). Scores were adjusted for the same covariates used in the GSRD sample (population principal components and centre of recruitment). In GSRD and replication samples the scores were standardized to allow comparability.

Clinical risk scores were calculated in the replication samples using the same approach applied in GSRD, using the effect sizes obtained in GSRD training sample. In GENDEP there were no subjects with chronic depression according to the DSM-IV definition (duration of the episode of at least two years), thus we used 1 year as threshold to define chronic depression since there is some evidence that outcome is poorer after 1 year (30). The maximum number of depressive episodes in GENDEP was 3, thus we used 2 ( $3<sup>rd</sup>$  quantile) as threshold instead of 4 (which corresponded to the  $3<sup>rd</sup>$  quantile in GSRD sample). In STAR\*D the MADRS scale was not available, thus we used QIDS-C16 item 11 (view of myself) and item 12 (suicidality) to calculate the pessimism score and items 10 (concentration), 13 (general interest), 14 (energy level) and 15 (feeling slow down) to calculate the interest activity score.

**Supplementary Table 1**: clinical-demographic characteristics of patients included in the training sample (n=847) and testing sample (n=362). Baseline MADRS refers to the beginning of the current depressive episode. BMI=body max index. MADRS=Montgomery and Åsberg Depression Rating Scale. TRD=treatment-resistant depression. Mean  $\pm$  standard deviation is reported for continuous variables and distribution for dichotomous ones. T tests, chi2 or Fisher's exact tests were used to calculate p values.



Psychotic features (yes/no)	40/551	16/244	0.85
Chronic depression (yes/no)	150/307	66/134	
Current suicidal risk (yes/no)	416/430	176/186	0.91
Generalized anxiety disorder (yes/no)	87/759	41/321	0.66
Phenotype of interest	TRD $n=353$ Non-response $n=291$ Response $n=203$	TRD $n=151$ Non-response $n=125$ Response $n=86$	0.99
Treatment	Serotonergic n=421 Noradrenergic n=271 Serotonergic-noradrenergic n=128 Other $n=27$	Serotonergic n=192 Noradrenergic n=93 Serotonergic-noradrenergic n=59 Other $n=18$	0.10

**Supplementary Table 2:** number of variants available after quality control in the GSRD sample. SNP=single nucleotide polymorphism; insdel=insertion/deletions; MNPs=multi-nucleotide polymorphisms. SO=sequence ontology project. The number of variants with SO functional score  $\geq 0.90$  was lower than the number with SIFT > 0.95 and Polyphen > 0.15, but only the 73% of variants in the first group had a MAF<0.02 while 85% in both the other two groups.



**Supplementary Table 3:** clinical variables tested for possible association with TRD (TRD vs. response) and non-response (non-response vs. response) in the training sample only for predictor selection. The variables independently associated with the phenotype of interest after Bonferroni correction (alpha=0.0018) are highlighted in red and they were included in the clinical risk score. MADRS=Montgomery and Åsberg Depression Rating Scale. MADRS subscales were defined according to the previous literature and they were tested because of their previously found association with antidepressant response  $(31)$ .





**Supplementary Table 4:** exome-wide distribution of variants with SO functional score  $\geq 0.90$  or  $\geq$ 0.70, SIFT deleterious (scores >0.95) and PolyPhen damaging/probably damaging variants (scores>0.15) among phenotypic groups. The mean number of alternative alleles and SD are reported in each phenotypic group.



**Supplementary Table 5:** distribution of variants with SO functional score  $\geq 0.90$  per gene among phenotypic groups. The number of subjects carrying at least one alternative allele in a certain gene is also reported. For 14353 genes we observed at least one variant with SO functional score  $\geq 0.90$ . Only genes with p<1e-03 are reported.





\* SCN1A and SCN9A antisense RNA 1, its position mostly overlaps with SCN9A

**Supplementary Table 6:** distribution per gene of variants with SIFT score>0.95 in **A** (16483 genes had at least one of these variants) and PolyPhen score > 0.15 in **B** (16947 genes had at least one of these variants) among phenotypic groups. The number of subjects carrying at least one alternative allele in a certain gene is also reported. Only genes with p<1e-03 are reported.

**A**





\* LOC101927267 and PRPH show substantial position overlap

**B**



**Supplementary Table 7:** association analyses of Eigen-weighted gene scores with the phenotypic groups. No association survived after Bonferroni correction (n of genes analysed: 21136). Only results with p<1e-03 are shown.









**Supplementary Table 8:** association analyses of Eigen-weighted gene set scores with the phenotypic groups. No association survived after Bonferroni correction (n of gene sets analysed: 7266). Only results with p<1e-03 are shown.







**Supplementary Table 9:** genes (**A**) and gene sets (**B**) included in the predictive models. The order of predictors corresponds to their relative importance in the model (see also Figure 2).

# **Supplementary Table 9A**







# **Supplementary table 9B**





**Supplementary Table 10:** results referred to non-significant or borderline significant predictive models in the testing sample (GSRD). NA=noradrenergic. 5-HT=serotonergic. AUC=area under the curve, 95% confidence intervals are reported in parenthesis.





**Supplementary Table 11:** clinical-demographic characteristics of patients included from GENDEP and STAR\*D studies. Only patients having both the exome and genome-wide arrays were considered. QIDS-CR=Quick Inventory of Depressive Symptomatology Clinician-Rated.



**Supplementary Table 12:** application of the significant predictive models developed in GSRD training set in STAR\*D and GENDEP. Extreme genetic percentiles were considered  $\leq 20$  or  $\geq 80$  percentiles. \*Significant models.





**Supplementary Figure 1:** beta distributions used to estimate frequency-based weights for rare (**A**) and common variants (**B**).



**Supplementary Figure 2**: Flowchart of the number of patients excluded during quality control.



**Supplementary Figure 3:** concordance between rare variants from exome sequencing and rare variants (genotyped or imputed) from genome-wide genotyping. The total number of variants available for these comparisons was 161,130 (120,632 imputed variants and 40,497 genotyped variants).



**Supplementary Figure 4:** exome-wide distribution of the score (re-scaled between 20 and 100) using the described different weighting approaches. Subjects with scores outside 5 SD from the mean (red



lines) were excluded from the subsequent analyses. SO=sequence ontology project. **Eigen weights CADD weights**



**Supplementary Figure 5:** correlation (Pearson's correlation coefficient) among gene scores obtained using different functional weighting.



**Supplementary Figure 6**: comparison of the distribution of rare variants between the GSRD sample (exome sequence data) and GENDEP (genome-wide and exome arrays after imputation).



# **References**

1. Babraham Bionformatics. FastQC: A quality control tool for high throughput sequence data [Internet]. [cited 2019 Jun 18]. Available from:

http://www.bioinformatics.babraham.ac.uk/projects/fastqc/

2. FASTX-Toolkit. FASTQ/A Trimmer [Internet]. [cited 2019 Jun 18]. Available from: http://hannonlab.cshl.edu/fastx\_toolkit/index.html

3. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;**14**(4):R36.

4. Garrison E, Sibley T, Lee D, Marks P, Spies N, Randall J, et al. Freebayes, a haplotypebased variant detector [Internet]. [cited 2019 Jun 18]. Available from: https://github.com/ekg/freebayes

5. Zhang S, Wang B, Wan L, Li LM. Estimating Phred scores of Illumina base calls by logistic regression and sparse modeling. BMC Bioinformatics. 2017;**18**(1):335.

6. Wang Q, Shashikant CS, Jensen M, Altman NS, Girirajan S. Novel metrics to measure coverage in whole exome sequencing datasets reveal local and global non-uniformity. Sci Rep. 2017;**7**(1):885.

7. Fang H, Wu Y, Narzisi G, et al. Reducing INDEL calling errors in whole genome and exome sequencing data. Genome Med. 2014;**6**(10):89.

8. Hutter S, Piro RM, Waszak SM, et al. No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients. Hum Genet. 2016;**135**(5):469–75. 9. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data

quality control in genetic case-control association studies. Nat Protoc. 2010;**5**(9):1564–73.

10. Zhang Y, Shen X, Pan W. Adjusting for population stratification in a fine scale with principal components and sequencing data. Genet Epidemiol. 2013;**37**(8):787–801.

11. Fabbri C, Kasper S, Kautzky A, et al. Genome-wide association study of treatmentresistance in depression and meta-analysis of three independent samples. Br J Psychiatry. 2019;**214**(1):36–41.

12. McCarthy S, Das S, Kretzschmar W, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2016;**48**(10):1279–83.

13. Das S, Forer L, Schönherr S, et al. Next-generation genotype imputation service and methods. Nat Genet. 2016;**48**(10):1284–7.

14. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;**46**(3):310–5.

15. Ionita-Laza I, McCallum K, Xu B, Buxbaum JD. A spectral approach integrating functional genomic annotations for coding and noncoding variants. Nat Genet. 2016;**48**(2):214–20.

16. Curtis D. Construction of an Exome-Wide Risk Score for Schizophrenia Based on a Weighted Burden Test. Ann Hum Genet. 2018;**82**(1):11–22.

17. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;**1**(6):417–25.

18. Pirooznia M, Wang T, Avramopoulos D, et al. SynaptomeDB: an ontology-based knowledgebase for synaptic genes. Bioinformatics. 2012;**28**(6):897–9.

19. Wray NR, Ripke S, Mattheisen M, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;**50**(5):668–81.

20. Pardiñas AF, Holmans P, Pocklington AJ, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018;**50**(3):381–9.

21. Purcell SM, Moran JL, Fromer M, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;**506**(7487):185–90.

22. Stahl EA, Breen G, Forstner AJ, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019;**51**(5):793–803.

23. Wang X, Zhang D, Tzeng J-Y. Pathway-guided identification of gene-gene interactions. Ann Hum Genet. 2014;**78**(6):478–91.

24. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR\*D): rationale and design. Control Clin Trials. 2004;**25**(1):119–42.

25. Uher R, Perroud N, Ng MYM, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;**167**(5):555–64.

26. Iniesta R, Malki K, Maier W, et al. Combining clinical variables to optimize prediction of antidepressant treatment outcomes. J Psychiatr Res. 2016;**78**:94–102.

27. Garriock HA, Kraft JB, Shyn SI, et al. A Genomewide Association Study of Citalopram Response in Major Depressive Disorder. Biological Psychiatry. 2010;**67**(2):133–8.

28. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet. 2006;**2**(12):e190.

29. Ionita-Laza I, Lee S, Makarov V, Buxbaum JD, Lin X. Sequence kernel association tests for the combined effect of rare and common variants. Am J Hum Genet. 2013;**92**(6):841–53.

30. Khan A, Dager SR, Cohen S, Avery DH, Scherzo B, Dunner DL. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology. 1991;**4**(2):125– 30.

31. Uher R, Perlis RH, Henigsberg N, et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med. 2012;**42**(5):967–80.